Press Releases

Keystone Bio Recognizes the Big “GAIN” from Cortexyme’s Trial Results

For Immediate Release Keystone Bio GAIN Trial Results Confirm Relationship Between Porphyromonas gingivalis (Pg) and Alzheimer’s Disease, and Furthers Keystone Bio’s Explanation of Pg’s Toxic Virulence Factors. [ST. LOUIS, Mo. – Nov 8, 2021] Keystone Bio, a biotechnology company developing precision biologics for the elimination of Pg, acknowledges Cortexyme’s efforts in advancing Alzheimer’s disease research…

1627069699917

Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors as Major Driver of Sporadic Alzheimer’s and Chronic Inflammation

For Immediate Release Keystone Bio Groundbreaking Data Announced during Poster Presentations at Alzheimer’s Association International Conference 2021 and Being Published in Upcoming August Issue of Journal of Alzheimer’s Disease (currently in prepress). [ST. LOUIS, Mo. – July 28, 2021] Keystone Bio, a biotechnology company, is a frontrunner in developing precision biologics to eliminate Porphyromonas gingivalis…